Under a focused technology out-licensing business model, Synaffix has delivered multiple best-in-class therapeutic candidates for our partners’ pipelines.
Lonza to Acquire Synaffix and Strengthen Antibody-Drug Conjugates Offering
Synaffix Announces Expansion of ADC Collaboration with MacroGenics
Links to synaffix.com (8)
worldadc-usa.comWorld ADC San Diego | Antibody-drug Conjugate Conference